Can Vitamin D Deficiency Predict Coronary Artery Disease?

Yıl 2018, Cilt: 6 Sayı: 2, 45 - 52, 12.09.2018

Şeref Alpsoy Aydın Akyüz Demet Özkaramanli Gür Birol Topçu Hasan Değirmenci

Öz

Anahtar Kelimeler

25-hydroxyvitamin D, Coronary artery disease, Hhigh-density lipoprotein cholesterol, C-reactive protein

Vitamin D Eksikliği Koroner Arter Hastalığı İçin Ön Görüdürücü Müdür?

Öz

Amaç: D vitamininin ve koroner
arter hastalığının (KAH) ilişkisiyle ilgili ortaya çıkan verilere dayanarak,
KAH'da D vitamini ile C-reaktif protein (CRP) ile temsil edilen inflamasyon ve
serum lipid profili arasında  ilişki
bulunup bulunmadığını araştırdık.

Materyal ve Metod: Yeni KAH tanısı  konmuş 115 hasta ve 62 sağlıklı birey
çalışmaya alındı. Kan lipidleri, CRP ve D vitamini düzeyleri ölçüldü ve hasta
ve kontrol gruplarının değerleri karşılaştırıldı.

Bulgular: Hasta grubunda düşük
dansiteli lipoprotein kolesterol (DDL-K), CRP ve trigliserit düzeyleri yüksek,
vitamin D ve yüksek dansiteli lipoprotein kolesterol (YDL-K) düşüktü.Vitamin D
ile YDL-K arasında pozitif korelasyon(r=0.328; p<0.001), vitamin D ile CRP arasında
negatif korelasyon (r=-0.484; p<0.001) vardı. Multivariate lojistik
regresyon analizinde, sigara (p=0.001,
OR = 5.301; 95% CI = 2.215 – 12.687), hipertansiyon varlığı (p=0.040, OR =
2.355; 95% CI=1.039 – 5.336), DDL-K düzeyi (p=0.048, OR =1.021, 95% CI=1.000 –
1.042) ve vitamin D düzeyi (p=0.001, OR = 0.937, 95% CI = 0.902 – 0.973) KAH
belirleyicisi olarak bulundular.

 

Sonuç: Azalmış D vitamini
seviyeleri, KAH'da düşük YDL-K ve yüksek CRP seviyeleri ile ilişkilidir.
Sigara, hipertansiyon, DDL-K ve D vitamini, KAH'ın belirleyicisidirler. 

Anahtar Kelimeler

25-hidroksi Vitamin D, Koroner arter hastalığı, Yüksek dansiteli lipoprotein kolesterol, C-reaktif protein

Kaynakça

• References1. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366: 54-63.2. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment, Review. Circulation. 2004 ;109 (23 Suppl 1): III15-9.3. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999; 340 :115–26.4. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6:508-19.5. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al. For the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195–207.6. van der Meer IM, de Maat MP, Bots ML, Breteler MM, Meijer J, Kiliaan AJ, et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. ArteriosclerThromb Vasc Biol. 2002 ; 22: 838-42.7. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels.The Framingham Study. JAMA. 1986; 256: 2835-38.8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–97.9. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med. 2006;3:144-53.10. Duffy D. Rader DJ. Update on strategies to increase HDL quantity and function. Nat Rev Cardiol. 2009;6:455-63.11. Judd SE, Tangpricha V. Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci. 2009;338:40-44.12. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81:353-73.13. Nadir MA, Szwejkowski BR, Witham MD. Vitamin D and cardiovascular prevention. Cardiovasc Ther. 2010; 28:e5-12.14. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, Lappé et al. Intermountain Heart Collaborative (IHC) Study Group. Relation of vitamin D deficiency to cardiovascular risk factors disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106:963-68.15. Vacek JL,Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am JCardiol. 2012; 109: 359-63.16. Seker T, Gür M, Yüksel Kalkan G, Kuloğlu O, Yıldız Koyunsever N, Yıldıray Şahin D, et al. Serum 25-hydroxyvitamin D level and extent and complexity of coronary artery disease. J Clin Lab Anal. 2014; 28: 52-58.17. Shor R, Tirosh A, Shemesh L, Krakover R, Bar Chaim A, Mor A, et al.. 25 hydroxyvitamin D levels in patients undergoing coronary artery catheterization. Eur J Intern Med. 2012;23:470-73.18. Michos ED, Streeten EA, Ryan KA, Rampersaud E, Peyser PA, Bielak LF, et al. Serum 25-hydroxyvitamin d levels are not associated with subclinical vascular disease or C-reactive protein in the old order amish. Calcif Tissue Int. 2009;84:195-202.19. Amer M, Qayyum R. Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). Am J Cardiol. 2012;109:226-30.20. Ashraf AP, Fisher G, Alvarez J, Dudenbostel T, Calhoun DA, Szalai AJ, et al. Associations of C-Reactive Protein to Indices of Vascular Health and the Influence of Serum 25(OH)D Status in Healthy Adults. J Nutr Metab. 2012, doi:10.1155/2012/475975.21. Chen WR, Qian YA, Chen YD, Shi Y, Yin DW, Wang H, et al.The effects of low vitamin D on coronary artery disease. Heart Lung Circ. 2014 ;23:314-19.22. Maki KC, Rubin MR, Wong LG, McManus JF, Jensen CD, Marshall JW, et al. Serum 25-hydroxyvitamin D is independently associated with high-density lipoprotein cholesterol and the metabolic syndrome in men and women. J Clin Lipidol. 2009; 3:289-96.23. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards.Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989; 2:358–67.24. Kim DH,Sabour S, Sagar UN,Adams S,Whellan DJ. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol. 2008;102:1540-44.25. Syal SK, Kapoor A, Bhatia E, Sinha A, Kumar S, Tewari S, et al. Vitamin D deficiency, coronary artery disease and endothelial dysfunction: observations from a coronary angiographic study in Indian patients. J Invasive Cardiol. 2012; 24: 385-89.26. Ku YC, Liu ME, Ku CS, Liu TY, Lin SL. Relationship between vitamin D deficiency and cardiovascular disease. World J Cardiol. 2013;5:337-46.27. Gotto AM Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 2002;144(6 Suppl): S33-42.28. Alber HF, Wanitschek MM, de Waha S, Ladurner A, Suessenbacher A, Dörler J, et al. High-density lipoprotein cholesterol, C-reactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography. Eur J ClinInvest. 2008; 38:372-80.29. Schnatz PF, Jiang X, Vila-Wright S, Aragaki AK, Nudy M, O'Sullivan DM, et al. Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women's Health Initiative calcium/vitamin D randomized trial. Menopause. 2014; 21:823-33.30. Kim M, Na W, Sohn C. Correlation between vitamin D and cardiovascular disease predictors in overweight and obese Koreans. J Clin Biochem Nutr. 2013;.52:167-71.31. Kazlauskaite R, Powell LH, Mandapakala C, Cursio JF, Avery EF, Calvin J. Vitamin D is associated with atheroprotective high-density lipoprotein profile in postmenopausal women. J ClinLipidol. 2010;4:113-19.32. Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1.25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J ClinInvest.1987; 79:1659-64.33. Patel S, Farragher T, Berry J, Bunn D, Silman A, Symmons D. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum. 2007; 56:2143-49.